BELL PHARMACEUTICALS, INC. – Trademark Portfolio
Entity Type: 03
BELL PHARMACEUTICALS, INC. holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 8 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 2 Nice Classification classes. Currently, 7 trademarks are registered. Notable registered marks include OTIX, JET-ALERT, JET-AVERT, JET-ASLEEP, and TRAV-L-TABS. The owner is based in BELLE PLAINE, MN.
200 W. BEAVER STREET
BELLE PLAINE, MN 56011
Showing of trademarks Trademarks
Trademark Classifications
BELL PHARMACEUTICALS, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does BELL PHARMACEUTICALS, INC. have?
BELL PHARMACEUTICALS, INC. has 10 U.S. trademarks filed with the USPTO. Of these, 7 registered, 2 abandoned, 1 cancelled.
What trademark classes does BELL PHARMACEUTICALS, INC. file in?
BELL PHARMACEUTICALS, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are BELL PHARMACEUTICALS, INC.'s most well-known trademarks?
BELL PHARMACEUTICALS, INC.'s registered trademark portfolio includes well-known marks such as OTIX, JET-ALERT, JET-AVERT, JET-ASLEEP, and TRAV-L-TABS. These are among 7 currently registered trademarks in the portfolio.
What is BELL PHARMACEUTICALS, INC.'s trademark registration success rate?
BELL PHARMACEUTICALS, INC. has a 70% trademark registration rate, with 7 out of 10 resolved applications resulting in successful registration. Currently, 0 applications are pending review.